Media Center

NEWSROOM

An online resource for members of the media and the investment community.

VIEW OUR LATEST RELEASES

Dec 21, 2023

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR

Oct 25, 2023

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Contact

HAVE A MEDIA INQUIRY?
Here’s who to contact:

CORPORATE
Chris Vancheri
Associate Director, Corporate Communications
Phone: 551-305-0050
Email: Christopher_Vancheri@eisai.com

NEUROLOGY
Libby Holman
Senior Director, Product Communications
Phone: 201-753-1945
Email: Libby_Holman@eisai.com

ONCOLOGY
Michele Randazzo
Director, Product Communications
Phone: 201-248-2228
Email: Michele_Randazzo@eisai.com